Xeloda (capecitabine) potentialities in the treatmentof cancer patients (review)


Cite item

Full Text

About the authors

N F Orel

References

  1. Schmoll Н. J. 20"'-century approaches to CRC therapy. In: Abstracts TP activation: convenience through innovation. 17 March 2001 Frankfurt. 6-8.
  2. Toi M., Ohashi Т., Takatsuka Y. et al. Selective effect of adjuvant 5'-deoxy-5-fluoridine (5'-DFUR) tumors in primary breast cancer. Proc. ASCO 1997; 16: 136a, abstr. 481.
  3. Takebayashi Y., Akiyama S., Akiba S. et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorilase, in human colorectal carcinoma. J. Natl. Cancer Inst. 1996; 88: 1110-1117.
  4. Takebayashi Y., Maiyadera K., Akiyama S. et al. Expression of thymidine phosphorylase in human gastric carcinoma. JpnJ. Cancer Res. 1996; 87: 288-295.
  5. Mizutani Y., Okada Y., Yoshida O. et al. Expression of plateletderived endothelial cell growth factor in bladder carcinoma. Cancer 1997; 79: 1190-1194.
  6. Reynolds K., Farzanech F., Collins W. P. et al. Association of ovarian malignancy with expression of platelet-derived endothelial cell growth factor. J. Natl. Cancer lnstr. 1994; 86: 1234-1238.
  7. Imazano Y., Takebayashi Y., Nishiyama K. et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol. 1997; 15: 2570- 2578.
  8. Moghaddam A., Zhang H-T, Fan T-PD. et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc. Natl. Acad. Sci. USA 1995; 92; 998-1002.
  9. Matsuura Т., Kuratate L, Teramachi K. et al. Thymidine phosphorylase expression is associated with both increase of intratumoral microvessels and decrease of apoptosis in human colorectal carcinoma. Cancer Res. 1999; 59: 5037-5040.
  10. Daneuberg K., Metzger R., Grosheu S. et al. Thymidilate synthetase and thymidine phosphorylase are prognostic, indica- tions of survival for colorectal cancer. Proc. ASCO 1997; 16: 257a, abstr. 914.
  11. Гарин A.M. Новые анти метаболиты в онкологической практике. В кн.: Горбунова В. А. (ред.) Новые цитостатики в лечении злокачественных опухолей. М: 1998. 41-60.
  12. Schuller J., Cassidy J., Dumont E. et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother. Pharmacol. 2000; 45: 291-297.
  13. Ishikawa Т., Yamamoto Т., Fukase Y. et al. Antitumor activities of capecitabine much more effective than 5-FU in either monotherapy or combination therapy with standard cytostatics in human xenografts. Res. Rep. J., 1915; 146: 404.
  14. Sawada N., Ishirawa Т., Ishitsura H. Antitumor activity of capecitabine in combination with taxol or taxotere in human cancer xenografts. Ibid. 1996; 146: 551.
  15. Sawada N., Ishikawa Т., Sekiguchi F. et al. Clin. Cancer Res. 1998; 4: 1013-1014.
  16. Cao S., Hapke G., Rustum Y. M. Enhanced antitumor activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Ibid. 2001; 20: 42, abstr. 464.
  17. Ichikawa Т., Sawada N., Sekiquchi F. et al. Xeloda (capecitabine) a new oral fluoropyrimidine carbamate with an improved efficacy profile over other fluoropyrimidines. Ibid. 1997; v. 16, ab. 796.
  18. Yamashita K., Tsunoda Т., Urakami A. et al. Induction of thymidilate phosphorylase activity and enhancement of capecitabine efficacy by mitomycin С in human colorectal cancer. Ibid. 2001; 20: 151a, N 600.
  19. Velves C, Budman D. R., Creaven P. J. et al. Pharmacokinetics and pharmacodynamics of capecitabine in two phase studies. Ibid. 1996; 15: 467a.
  20. Туторов С. Л., Семенов Н. Н., Загрекова Е. И. Новые лекарства в лечении солидных опухолей. Рус. мед. жури. 2001; 9 (22): 1017-1020.
  21. Blum J. L., Jones S. E. Buzdar A. U. et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastases breast cancer. J. Clin. Oncol. 1999; 17: 485-493.
  22. Leonard R. С. F. Oral fluoropyrimidines among the new drugs for patients with metastatic breast cancer. Br. J. Cancer 2001; 84(11): 1437-1442.
  23. O'Reilly S. M., Moiseyenko V., Talbot D. С A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc. ASCO 1998; 163a, N 627.
  24. Aapro M. First-line capecitabine treatment for metastatic breast cancer: Update data from a randomized phase II trial. In: Proc. ICACT2000. 4-10.
  25. Reichardt P., von Minckwitz G, Luck H. Y. et al. Capecitabine: The new standard in metastatic breast cancer failing anthracycline and taxanes-containing chemotherapy? Mature results of a large multicenter phase II trial. Eur. J. Cancer 2001; 37 (suppl. 7): 191, N 699.
  26. Fumoleau P., Largillier R., Trillet-Lenoir V. et al. Capecitabine (Xeloda) in patients with advanced breast cancer, previously treated with anthracyclines and taxanes: results of a large phase II study. Proc. ASCO 2002; 21 (1): 62a, N 247.
  27. Prouk L., Vasey P. A., Sparreboom A. et al. A phase I and pharmacokinetis study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br. J. Can- cer 2000; 83: 22-29.
  28. O'Shaughnessu J., Vukelja S., Moiseyenko V. et al. Results of a large phase III trial of Xeloda / Taxotere combination therapy vs Taxotere monotherapy in metastatic breast cancer patients. In: San Antonio breast cancer symposium. 2000. abstr. 381.
  29. Perez-Manga G, Batsistra N., Constenia M. et al. Efficacy and safety profile of capecitabine (Xeloda) in combination with paclitaxel in patients with locally advanced or metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res. Treat. 2000; 64: 125, abstr. 535.
  30. Angiolini C, Venturini M., DellMastro L. et al. Capecitabine in association with epirubicin and docetaxel as first line chemo- therapy in advanced breast cancer: a dose-finding study. Breast Cancer Res. Treat. 2000; 64: 123, abstr. 529.
  31. Venturini M., Del Mastro L., Durando A. et al. TEX (Taxotere, Epirubicin and Xeloda) regimen as first line chemotherapy in advanced breast cancer. A multicenter fhase II study. Proc. ASCO 2001; 20 (p. 2): 48b.
  32. Nole F., Catania C, Mandala M. et al. Phase I study of vinorelbine and capecitabine in advanced breast cancer. Breast Cancer Res. Treat. 2000; 64: 125, abstr. 539.
  33. Ahn J. H., Kim В., Lee J. S. et al. Phase II study of a combination chemotherapy of capecitabine and vinorelbine in metastatic breast cancer with previous exposure to anthracycline and taxanes: preliminary results. Proc. ASCO 2002; 21 (p. 2): 55b, N 2030.
  34. Donaldson L. A., Jenings C. L., Lee F. С et al. A phase I/I J study of carboplatin, vinorelbine and capecitabine in patients with metastatic breast cancer. Ibid. 2000; 19, 37b, N 1960.
  35. Domenech G., Perez A., Vogel C. Vinorelbine / Capecitabine (VINOCAP) combination Remission Induction Therapy for Metastatic Breast cancer. Ibid. 2001; 20 (p. 2): 48b, N 1939.
  36. Ghosn M., Farhat F., Kattan J. Vinorelbine (navelbine) IV and capecitabine (VINOCAP) as front line chemotherapy in metastatic breast cancer. Ibid. 2002; 21 (p. 2): 42b, N 1978.
  37. Bonnefoi H., Biganzoli L., Mauriac L. et al. An EORTC-IDB- BC phase I study of cyclophosphamide and epirubicin in com- bination with capecitabine (CEX) as primary treatment of locally advanced / inflammatory or large operable breast cancer. Ibid. 2001; 20 (p. 2); 13b, N 1800.
  38. Chan S. C, Wong L. N., Chow L. W. С A phase II study on an all-oral regimen of capecitabine (Xeloda), idarubicin and cyclophosphamide for metastatic breast cancer - safety, efficacy and quality of life. Ibid. 2002; 21 (p. 2): 53b, N 2023.
  39. Jakob A., Schupp M., Knop S. et al. A phase II study of capecitabine in patients who relapsed after high dose chemo therapy followed by peripheral blood stem cell transplantation for metastatic breast cancer. Ibid. 2001; 20 (p. 2): 55b, N 1966.
  40. Hoff P. Capecitabine as first-line treatment for colorectal cancer (CRC): Integrated results of 1207 patients from 2 randomized phase III study. On behalf of the capecitabine (Xeloda) CRC study group. Ann. Oncol. 2000: 11 (suppl. 4): 60, N 263.
  41. Padzur R., Douillard J. Y., Skillings J. R. et al. Multicenter phase III study of 5-fluorouracil of UFT in combination with leucovorin in patients with metastatic colorectal cancer. Proc. ASCO 1999; 18: 263a, abstr. 1009.
  42. Schmoll H. J. Putting the oral fluoropyrimidines into perspective. In: Abstracts Tnird International, conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 117-118.
  43. Kovcin V., Krivokapic Z., Jesic R. First line capecitabine (Xeloda) chemotherapy for metastatic colorectal cancer. Int. J. Cancer 2002; (suppl. 13): 273, 228s.
  44. Koudo Y., Takemiya S., Sakamoto J. et al. A multicenter phase II trial of capecitabine (Xeloda) in previously untreated advanced / metastatic colorectal cancer. Proc. ASCO 2002; 21 (p. 2): 127b, N 2322.
  45. Kerr D. Perspectives in combination therapy. Xeloda plus irinotecan. In: Abstracs Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 123-125.
  46. Cassata A., Chiara S. S., Alu M. et al. Ongoing phase II trial with two schedules of irinotecan (CPT-11 in combination with capecitabine as first line chemotherapy in patients with advanced colorectal cancer. Proc. ASCO 2001; 20 (p. 1): 144, N 573.
  47. Kerr D. J., Ten W. W., Bokkel Huinink et al. A phase I/II study CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer. Ibid. 2002; 21 (p. 1): 161a, N 643.
  48. Schleucher N., Tewes M., Achterrath W. et al. Extended phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Ibid. 2001; 20 (p. 1): 141a, N 561.
  49. Joedan K., Grothey A., Kellner O. et al. Randomized phase II trial of capecitabine plus irinotecan vs capecitabine plus oxaliplatin as first-line therapy in advanced colorectal cancer: results of an interim analysis. Ibid. 2002; 21 (p. 2); 103 b, N 2225.
  50. Evans J., Tabernero J., Cassidy J. et al. Safety profile and preliminary efficacy of capecitabine (Xeloda) in combination with oxalipiatin in patients with advances or metastatic solid tumours: results from a phase I study. Ann. Oncol. 2000; 11 (suppl. 4): 51, abstr. 2.
  51. Schoffeski P. Perspective in combination therapy. Xeloda plus oxalipiatin. In: Abstracts Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 121-122.
  52. DeSantis S., Zeuli M., Di Castanzo F. et al. Oxalipiatin and capecitabine in advanced colorectal cancer: a dose-finding trial. Proc. ASCO 2001; 20 (p. 1): 141, abstr. 9.
  53. Thomas R., Quinn M., Wilson R. et al. A phase I trial of capecitabine and oxalipiatin. Ibid. 133, abstr. 530.
  54. Borner M. M., Mueller S., Roth A. et al. Phase II study of capecitabine + oxalipiatin in first line and second line treatment of advanced or metastatic colorectal cancer. Ibid. 137, abstr. 546.
  55. Sastre J., Butts C, Cassidy J. et al. Capecitabine - oxalipiatin combination (XELOX), effective Iя line therapy for patients with metastatic colorectal cancer: survival update of an international phase II trial. Ann. Oncol. 2002; 13 (suppl. 4): 80, N 288P.
  56. Tabernero J., Butts С A., Cassidy J. et al. Capecitabine and oxalipiatin in combination (Xelox) as first line therapy for patients with metastatic colorectal cancer: results of an interna- tional multicenter phase II trial. Proc. ASCO 2002; 21 (p. 1): 133a, N 531.
  57. Shields A. F., Zalupski M. M., Marshall J. L. et al. A phase II trial of oxalipiatin and capecitabine in patients with advanced colorectal cancer, (bid. 143a, N 568.
  58. Glynne-Jones R. Perspectives in combination therapy. Xeloda plus radiotherapy. In: Abstracts Third International conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 127-128.
  59. Reese Т., Tanner J., Frings S. et al. Capecitabine combined with simultaneous radiotherapy in rectal cancer: a phase I study. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48 (suppl. 3): 120, abstr. 20.
  60. Dunst J., Ruse Т., Frings S. Phase I study of capecitabine combined with simultaneous radiotherapy rectal cancer. Proc. AS- CO 2001; 20 (p. l):149a, N 592.
  61. Androulakis N., Kouroussis C, Kakolyris S. et al. Phase I study of capecitabine combinatior wit radiotherapy as adjuvant treatment for operable rectal cancer. Ibid. 2002; 21 (p. 2): 121 b, N 2297.
  62. Huller D. G. New approaches to adjuvant therapy for colorectal cancer. In: Abstracts Third International Conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 107-111.
  63. Lee F. С, Wong G. Capecitabine and mitomycin C for AIDS patients with anal squamous cell carcinoma. Proc. ASCO 2002; 21 (p. 2): 144b, N 2389.
  64. Cunningham D., James R. D. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Eur.J. Cancer 2001; 37: 826-834.
  65. Koizumi W., Taguchi T. A. A phase II study of capecitabine (Xeloda) in patients with advanced metastatic gastric carcinoma. Proc. ASCO 2001; 20: 142b, N 2320.
  66. Hdng Y., Song S., Cho J. et al. A phase II trial of capecitabine (Xeloda) in chemotherapy naive patients with advanced and/or metastatic gastric cancer. Ibid. 2002; 21 (p. 1): 156a, N 623.
  67. Базип И. С, Гарин А. М. Рак желудка: значение проблемы и современные возможности лечения. Рус. мед. журн. 2002; 10 (4): 588-593.
  68. Kim Т., Ahn J., Lee J. et al. A phase II trial of capecitabine and cisplatin in previously untreated advanced gastric cancer. Proc. ASCO 2001; 20: 166a, N 662.
  69. Evans T. R. J., Paul J., Mclnnes A. et al. Final results of a phase I and PK study of capecitabine (Xeloda) in combination with epirubicin and cisplatin in patients with advanced oesophagogastric adenocarcinoma. Eur. J. Cancer 2001; 37 (suppl. 6); 312, N 1156.
  70. Tebbutt /V., Norman A., Cunningham D. et al. Ramdomised, multicenter phase III comparing capecitabine with fluorour- acil and oxaliplatin with cisplatin in patients with advanced oesophago-gastric cancer: interim analysis. Proc. ASCO 2002; 21 (p. I): 131a, N 523.
  71. Karim А. В., Hallem F., Sayeed F. S. et al. Combination chemotherapy for advanced Gl-adenocarcinoma combining with CPT-11 and capecitabine: a pilot study in Bangladesh. Ibid. (p.2): 139b, N 2371.
  72. Delord J. P., Pierga J. Y., Dieras V. et al. Dose escalating and pharmacokinetic study of capecitabine (Xeloda) and irinotecan (CPT-11) in gastro-intestinal tumors preliminary results. Ibid. (p. I): 100a, N 397.
  73. Kennedy A. S., Van Echo D. A., Volpe С et al. Phase I studies using capecitabine combined with conformal radiation therapy, paclitaxel, CPT-11 and celecoxib in gastrointestinal melagnancies. Ibid. (p. 2): 300b, N 3021.
  74. Merin J. M., Lee F. С Palliative benefit for salvage treatment with capecitabine and thalidomide for gastric and / or esophageal adenocarcinoma: a retrospective case series. Ibid. 144b, N2391.
  75. Kim T. W., Ahn J. H., Chang H. M. et al. A phase II trial of capecitabine and cisplatin in previously untreated advanced billiary cancer. Ibid. 115b, N 2273.
  76. Anthony L. В., Matthews E., Cronin M. et al. Continuous lowedose capecitabine produces significant biochemical responses in patients with progressive gastoentetopancreatic neoplasms. Ibid. 2001; 20 (p. 2): 104b, N 2167.
  77. Cartwright T. A phase II trial of Xeloda (capecitabine) in advanced or metastatic pancreatic cancer. Ibid. 2000; 19: 264a, abstr. 1026.
  78. Herrmann R., Borner M., Morant R. et al. Combining gemcitabine and capecitabine in advanced pancreatic cancer. Results of a phase I trial. Ibid. 267a, N 1038.
  79. Scheithauer W., Schull В., Ulrich-Pur H. et al. Gemcitabine alone or in combination with capecitabine in patients with advanced pancreatic adenocarcinoma. Ibid. 2002; 21 (p. 1): 126a, N 500.
  80. Hess V., Bomer M., Morant R. et al. Gemcitabine and capecitabine for advanced pancreatic cancer. A phase I//II trial. Eur.J. Cancer 2001; 37 (suppl. 6).: s. 315, N 1167.
  81. Campos L. Т., Alvarez R-, Sanford D. et al. Gemcitabine and capecitabine in advanced pancreatic cancer in solid tumors. A single institution experience. Proc. ASCO 2001; 20 (p. 2): 141b, N 2315.
  82. Schilsky R. L., Bertucci D., Vogelzang N. J. et al. Doseescalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J. Clin. Oncol. 2002; 20: 582-587.
  83. Vasey P. A., McMahon L., Paur J. et al. A phase II trial of capecitabine (Xeloda) in relapsed ovarian cancer. Ann. Oncol. 2000; 11 (suppl. 4): 84, abstr. 373.
  84. Overmann K, Buer J., Hoffman R. et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br. J. Cancer 2000; 83: 583-587.
  85. Akhtar S. U., Mathew P., Lin J. et al. Phase II trial of capecitabine and carboplatin in patients with newly diagnosed advanced non-small cell carcinoma of the lung. Proc ASCO 2001; 20: 278b, N 2862.
  86. Pivot X., Chamorey E., Guardiola E. et al. Phase I accelerated dose escalating and pharmacokinetic study of capecitabine and cisplatin in head and neck cancer patients. Ibid. 2002; 21: 108a, N 428.
  87. Porta R., Carbonell X., del Campo M. J. et al. Phase I study of capecitabine in combination with cisplatin in patients with advancec and / or metastatic squamous cell carcinoma of the head and neck. Ibid. 239a, N 953.
  88. Van Echo D. A., Kennedy A. S., Sutharalingam M. Phase 1 studies of Xeloda plus chemotherapy and radiation in head/ neck or gastrointestinal cancer. Int. J. Cancer 2002; (suppl. 13): 426, p928.
  89. Sykes A., Slevin N. A phase I study to determine the maximun tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Proc. ASCO 2002; 21: 253a, N 936.
  90. Wenzel C, Schmidinger M. P., Locker G. J. et al. Oral chemotherapy with capecitabine (Xeloda) in the treatment of metastatic renal cancer falling immunotherapy. Ibid. 2000; 19: 368a, N 1457.
  91. Wenzel С. С, Schmidinger M. P., Locker G. J. et al. Capecitabine in the treatment of metastatic renal cell carcinoma failng immunotherapy - the Vienna Experience. Ibid. 2001; 20: 196a, N 782.
  92. Wenzel C, Locker G. J., Bonkoe T. et al. Pilot study of capecitabine in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Ibid. 2002; 21: 148b, N 2404.
  93. Morant R. H. J., Dietrich D., Gillessen S. et al. Capecitabine in hormonerefractory metastatic prostate cancer: a phase II trial of the SAKK. Ibid. (p. 2): 157b, N 2442.
  94. Hirawat S., Kolitz J., Lichtman S. et al. Squential irinotecan and capecitabine (Xeloda) given every other week in the management of advanced metastatic carcinoma: a phase I study. Ibid. 79b, N 2127.
  95. Szatrowski T. P., Barau R. W., Shaw J. et al. Palliative treatment opportunities for geriatric oncology patients in longterm care: advantage of oral chemotherapy agents such as capecitabine (Xeloda). Ibid. 260b, N 2857.
  96. Proccopio G, Bajetta E., Catena L. et al. Safety and activity of Capecitabine in elderly patients with advanced breast cancer.Eur. J. Cancer 2001; 37 (suppl. 6): s. 197, N 720.
  97. Monfardini S. Medical oncology in cancer in the elderly. Ibid. (suppl.7): s. 253, N 255.
  98. Van Custem E. A in-depth analysis of Xeloda incolorectal cancer studies: what more can we learn? In: Abstracts Tird International Conference "Perspectives in colorectal cancer. A consensus meeting". Dublin; 2001. 119-120.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies